47 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).
Charles River Discovery Research Services
Structure-based design and optimization of potent inhibitors of the adenoviral protease.
Novartis Institute For Biomedical Research
Cathepsin C inhibitors: property optimization and identification of a clinical candidate.
Astrazeneca
Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
Takeda Pharmaceutical
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
University of Florida
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
Merck Research Laboratories
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Merck Frosst Centre For Therapeutic Research
Synthesis and activity of phosphinic tripeptide inhibitors of cathepsin C.
Wroclaw University of Technology
Design and synthesis of dipeptidyl nitriles as potent, selective, and reversible inhibitors of cathepsin C.
Merck Frosst Canada
Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.
National Human Genome Research Institute
Substrate optimization for monitoring cathepsin C activity in live cells.
Genomics Institute of The Novartis Research Foundation
Bicyclic carbamates as inhibitors of papain-like cathepsin proteases.
The Genomics Institute of The Novartis Research Foundation
Cathepsin C inhibitors as anti-inflammatory drug discovery: Challenges and opportunities.
Fuyang Normal University
Non-peptidyl non-covalent cathepsin C inhibitoEEr bearing a unique thiophene-substituted pyridine: Design, structure-activity relationship and anti-inflammatory activity in vivo.
Anhui Medical University
Development of potent and selective Cathepsin C inhibitors free of aortic binding liability by application of a conformational restriction strategy.
Glenmark Research Centre
Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?
Centre D'Etude Des Pathologies Respiratoires and Universit£
Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.
National Institute of Biological Sciences (Nibs)
DPP1 Inhibitors: Exploring the Role of Water in the S2 Pocket of DPP1 with Substituted Pyrrolidines.
Astrazeneca
Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors
Alumis
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
Astrazeneca
Synthesis and biological evaluation of polyhydroxy benzophenone as mushroom tyrosinase inhibitors.
Sun Yat-Sen University
Design, synthesis and biological screening of some novel celecoxib and etoricoxib analogs with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile.
Fayoum University
2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
Merck Sharp & Dohme
Synthesis, in vitro evaluation and molecular docking studies of thiazole derivatives as new inhibitors of a-glucosidase.
Hazara University
Heteroarylimino-4-thiazolidinones as inhibitors of cartilage degradation.
University of Catania
Characterization of cloned somatostatin receptors SSTR4 and SSTR5.
University of Pennsylvania
SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor.
Sanofi Recherche
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
University of Toronto
Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine1E receptor.
Synaptic Pharmaceutical
Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes.
UniversitÉ